Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vicore Pharma Holding

Vicore Pharma Holding
2000 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
VICO STOCK SYMBOL
4 INVESTMENTS
$1.31 SHARE PRICE (As of Monday Closing)
Description

Vicore Pharma Holding AB is a drug development company. The company's through is subsidiary is developing a new type of pharmaceutical compound, known as AT2R agonists, to stimulate the AT2 receptor within the Renin-Angiotensin system. Its lead drug candidate, C21, is the first small molecule compound in its class.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • C/o Bioventurehub Pepparedsleden
  • 431 83 Molndal
  • Sweden

+46 031-788 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vicore Pharma Holding’s full profile, request a free trial.

Vicore Pharma Holding Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.29 - $2.08 $57.8M $1.36 -$0.23 63.7K 42.4M

Vicore Pharma Holding Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 51,633 55,048 32,510 28,955
Revenue 4 58 109 99
EBITDA (7,871) (2,451) (2,827) (775)
Net Income (8,503) (2,492) (2,835) (776)
Total Assets 25,376 33,553 7,834 4,132
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vicore Pharma Holding Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vicore Pharma Holding‘s full profile, request access.

Request full access to PitchBook

Vicore Pharma Holding Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 08-Feb-2018 000000000 Industrial Chemicals 000 0000000
000000000 01-Mar-2011 00000 00000 00 00.000 Industrial Chemicals 000 0000000
0000 000000 000000000000000000 Drug Discovery 000 0000000
Selektope Early Stage VC Industrial Chemicals 000 0000000
To view this company’s complete investment and acquisition history, request access »

Vicore Pharma Holding Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 08-Feb-2018 000000000 Completed
  • 000000 000000 0000
000000000 01-Mar-2011 00000 00000 00 00.000 Completed
  • 5 buyers
Selektope Early Stage VC Completed
  • 3 buyers
To view this company’s complete exits history, request access »

Vicore Pharma Holding Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vicore Pharma Holding‘s full profile, request access.

Request full access to PitchBook

Vicore Pharma Holding Executive Team (5)

Name Title Board
Seat
Contact
Info
Per Jansson Managing Director & Co-Chief Executive Officer
Carl Dalsgaard Ph.D Chief Executive Officer
Hans Jeppsson Ph.D Chief Financial Officer
Ulrike Steckelings Ph.D CSO

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Vicore Pharma Holding Board Members (2)

Name Representing Role Since Contact
Info
Bengt Falk Ph.D Self Board Member 000 0000
Peter Strom Self Board Member 000 0000